Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study

American Journal of Psychiatry

Volumn 165, Issue 3, 2008, Pages 352-358

  Wu, Ren Rong ^a   Zhao, Jing Ping ^a   Guo, Xiao Feng ^a   He, Yi Qun ^a   Fang, Mao Sheng ^a   Guo, Wen Bin ^a   Chen, Jin Dong ^a   Li, Le Hua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; OLANZAPINE; PLACEBO; ANTIDIABETIC AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; KIDNEY FUNCTION TEST; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIVER FUNCTION TEST; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCALE FOR THE ASSESSMENT OF POSITIVE SYMPTOMS; SCHIZOPHRENIA; SIDE EFFECT; VOMITING; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN; ADOLESCENT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; OBESITY; PSYCHOLOGICAL RATING SCALE; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; OBESITY; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; WAIST-HIP RATIO; WEIGHT GAIN;

EID: 42449102198     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2007.07010079     Document Type: Article

References (42)

1. Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L: Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry 1994; 151:1359
2. Allison DB, Mentore JL, Heo M, Chandler LP: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696
3. Mario AJ, Cesar GB, Jose VB, Rocio PI, Obdulia MG, Teresa PP, Mari RB, Benedicto CF: Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006; 67:1253-1260
4. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(suppl 1):1-93
5. Hagg S, Joelsson L, Mjorndal T: Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59:294-299
6. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS: Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006; 186:572-578
7. Meyer JM: A retrospective comparison of lipid, glucose, and weight changes at one year between olanzapine and risperidone treated inpatients, in Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology. Nashville, Tenn, ACNP, 2000
8. Ganguli R: Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999; 60(suppl 2)10:20-24
9. Taylor D, McAskill R: Atypical antipsychotics and weight gain: a system review. Acta Psychiatr Scand 2000; 101:416-432
10. Marder S, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
11. Kinon MJ, Basson BR, Tollefson GD: Effect of long-term olanzapine treatment on weight change in schizophrenia. Schizophr Res 2000; 41(suppl 1):54
12. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ: Olanzapine treatment of children, adolescents and adults with pervasive developmental disorder: open-label pilot study. J Clin Psychopharmacol 1999; 19:37-44
13. Hester EK, Thrower MR: Current option in the management of olanzapine-associated weight gain. Ann Pharmacother 2004; 39:304-310
14. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC: A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005; 162:954-962
15. Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A: The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 2004; 14:332-336
16. Evans S, Newton R, Higgins S: Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry 2005; 39:479-486
17. Bailey CJ, Turner RC: Metformin. N Engl J Med 1996; 334:574-579
18. Nestler JE, Beer NA, Jakubowicz DJ, Beer RM: Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab 1994; 78:549-554
19. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, McCullough P: Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001; 50:856-861
20. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163:2072-2079
21. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC, American Psychiatric Publishing, 1994
22. Xinmin W, Lu L, Yulin W: Metformin, low-caloric and moderate athletics in treatment of obese. Chinese J New Drugs Clin Remedies 2003; 22:175-179
23. Shen Q, Hui L, Congrong G, Dajin Z: Therapeutic effect of metformin in obese population. Chinese J Endocrinol Metab 2003; 19:207-208
24. Andreasen NC: Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, University of Iowa, 1984
25. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
26. Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised (DEW). Rockville, Md, NIMH, 1976, pp 341-350
27. Haffner SM, Miettinen H, Stern MP: The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20:1087-1092
28. Kanders BS, Forse RA, Blackburn GL: Methods of Obesity, in Conn's Current Therapy. Edited by Rakel RE. Philadelphia, WB Saunders, 1991, pp 524-532
29. Fontbonne A, Charles MA, Juhan-Vague I: The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996; 19:920-926
30. Paolisso G, Amatao L, Eccellente R: Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998; 28:441-446
31. Yki-Jarvinen H, Nikkila K, Makimattila S: Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Drugs 1999; 58:75-82
32. Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, Knowler WC, Nathan DM: Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 2007; 56:1153-1159
33. Cleasby ME, Dzamko N, Hegarty BD, Cooney GJ, Kraegen EW, Ye JM: Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms. Diabetes 2004; 53:3258-3266
34. Orban JC, Ghaddab A, Chatti O, Ichai C: Metformin-associated lactic acidosis. Ann Fr Anesth Reanim 2006; 25:1046-1052
35. Alivanis P, Giannikouris I, Paliuras C, Arvanitis A, Volanaki M, Zervos A: Metformin-associated lactic acidosis treated with continuous renal replacement therapy. Clin Ther 2006; 28: 396-400
36. 12 deficiency. Age Ageing 2006; 35:200-201
37. Tran PV, Hamilton SH, Kuntz AJ: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17:407-418
38. Hummer M, Kemmler G, Kurz M: Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995; 5:437-440
39. Kinon BJ, Basson MS, Gilmore LM: Long-term olanzapine treatment weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62:92-100
40. Addington J, Mansley C, Addington D: Weight gain in first episode psychosis. Can J Psychiatry 2003; 48:272-276
41. Mcguire MT, Wing RR, Klem ML: Behavioral strategies of individuals who have maintained long term weight losses. Obes Res 1997; 7:334-341
42. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299:185-193